ZYME:NASDAQ
Zymeworks Inc
28,27Â US$
arrow_downward
-2,55%(-0,74) 1K
28-avg, 16:00:00 (GMT-4) · USD
search
Barcha belgilar
1K
5K
1O
6O
YBB
1Y
5Y
MAKS
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoZYME tikeri uchun statistika yaratilmoqda...
Ochish
28,91Â US$
Yuqori
28,91Â US$
Past
28,18Â US$
Bozor kapitali
2,01Â mlrd
Oʻrtacha hajm
585,49Â ming
Hajmi
0,00
52 haftalik eng yuqori
30,62Â US$
52 haftalik eng past
13,60Â US$
Aksiya boʻyicha daromad
-2,01Â US$
Beta
1,15
Muomaladagi aksiyalar
70,96Â mln
Xodimlar soni
231
Ochish
28,91Â US$
Yuqori
28,91Â US$
Past
28,18Â US$
Bozor kapitali
2,01Â mlrd
Oʻrtacha hajm
585,49Â ming
Hajmi
0,00
52 haftalik eng yuqori
30,62Â US$
52 haftalik eng past
13,60Â US$
Aksiya boʻyicha daromad
-2,01Â US$
Beta
1,15
Muomaladagi aksiyalar
70,96Â mln
Xodimlar soni
231
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
AD HOC NEWS
·
31 daqiqa oldin
Zymeworks stock holds steady as investors look to next data and licensing milestones
MarketBeat
·
21 soat oldin
Man Group plc Invests $5.51 Million in Zymeworks Inc. $ZYME
Profil
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
Zymeworks Inc haqida
CEOKenneth Galbraith
Xodimlar soni231
Asos solingan2003
Bosh ofislarMiddletown, Delaver, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytzymeworks.com
AI kontentda xatolar boʻlishi mumkin. Batafsil